BUSINESSMARKETWATCH
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly attempting to acquire a biotech company developing a promising atopic dermatitis drug for $10.9 billion in cash, as per a Financial Times report.
Mentioned
Related Signal
Adjacent reporting
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- Incyte strikes up to $2bn deal for blood disorder biotech
- GSK in talks to buy cancer biotech Nuvalent for more than $9bn
- UCB to acquire maker of antibody treatments for autoimmune diseases
- Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more